PARP1 and head and neck squamous cell carcinoma: Focussing on relatively radioresistant HPV-negative HNSCC spheroid models from different tumour origins, we analysed the comparative radiosensitisation properties of olaparib and talazoparib, the latter of which is characterised as a strong PARP trapper (21, 22).